Nuvalent initiates Phase 3 ALKAZAR trial of neladalkib in ALK-positive NSCLC

Nuvalent, Inc.

First patient dosed in Phase 3 ALKAZAR trial evaluating neladalkib for TKI-naïve advanced ALK-positive NSCLC.
Trial compares neladalkib head-to-head against ALECENSA (alectinib), a front-line standard of care.
ALKAZAR is a registrational study designed to support potential approval of neladalkib in this indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.